TriangleFianlimab (NCT06594991)
Fianlimab trial for Advanced Melanoma (NCT06594991). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable stage III or IV cutaneous or mucosal melanoma that progressed after PD-1 treatment alone or combined with LAG-3 blockade. Uveal melanoma is excluded.
The idea: combine fianlimab, cemiplimab and ipilimumab to block three immune checkpoints: LAG-3, PD-1 and CTLA-4. This may restore T-cell attacks on cancer. Both prior-treatment groups receive the combination, with fianlimab/cemiplimab infusions every three weeks and ipilimumab every six weeks. Researchers assess response and safety.
This phase 2 study plans 88 patients. James Smithy leads; twelve US sites are listed recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.